BCPP Psychiatric Pharmacy Certification Exam 2026:
Comprehensive Board Practice Test — Psychopharmacology,
Psychiatric Disorders, Medication Management, Adverse Effects,
Drug Interactions & Clinical Decision-Making — 190 Multiple-Choice
Questions with Answers & Detailed Rationales
Domain 1: Mental Health Conditions and Disorders (36%)
Anxiety Disorders
Question 1
A 34-year-old female presents with excessive worry occurring more days than not for the
past eight months. She reports difficulty controlling the worry, restlessness, and sleep
disturbance. She denies panic attacks or avoidance of social situations. Which diagnosis is
most consistent with her presentation?
A. Panic Disorder
B. Generalized Anxiety Disorder
C. Social Anxiety Disorder
D. Adjustment Disorder with Anxiety
Correct Answer: B
Explanation: GAD requires excessive anxiety and worry for ≥6 months with difficulty
controlling worry plus ≥3 associated symptoms (restlessness, fatigue, concentration
problems, irritability, muscle tension, sleep disturbance).
Question 2
Which screening instrument is most appropriate for quantifying symptom severity in a
patient with suspected generalized anxiety disorder?
,A. PHQ-9
B. GAD-7
C. MDQ
D. AUDIT-C
Correct Answer: B
Explanation: GAD-7 is a validated 7-item self-report scale specifically designed to assess GAD
symptom severity and monitor treatment response.
Question 3
A 28-year-old male with GAD has not responded to an adequate trial of escitalopram. Which
agent has the strongest evidence for augmentation in treatment-resistant GAD?
A. Quetiapine
B. Propranolol
C. Buspirone
D. Hydroxyzine
Correct Answer: A
Explanation: Second-generation antipsychotics, particularly quetiapine, have the most robust
evidence for augmentation in treatment-resistant GAD when first-line SSRIs/SNRIs fail.
Question 4
Which benzodiazepine is preferred for a patient with significant hepatic impairment
requiring rapid anxiety control?
A. Diazepam
B. Chlordiazepoxide
C. Lorazepam
,D. Clonazepam
Correct Answer: C
Explanation: Lorazepam undergoes direct glucuronidation without active metabolites,
making it safer in hepatic impairment than diazepam, chlordiazepoxide, or clonazepam.
Question 5
A 45-year-old woman with panic disorder reports that her attacks occur unpredictably and
she now avoids driving. Which treatment approach has the strongest evidence for panic
disorder with agoraphobia?
A. Benzodiazepine monotherapy
B. SSRI plus cognitive-behavioral therapy
C. Propranolol as needed
D. Buspirone monotherapy
Correct Answer: B
Explanation: Combined SSRI and CBT is superior to either alone for panic disorder with
agoraphobia and addresses both biological and behavioral components.
Question 6
Which medication is FDA-approved for social anxiety disorder?
A. Sertraline
B. Venlafaxine ER
C. Paroxetine
D. Fluoxetine
Correct Answer: C
, Explanation: Paroxetine is FDA-approved for social anxiety disorder (social phobia), along
with extended-release venlafaxine and sertraline.
Question 7
A patient with GAD is initiated on venlafaxine XR. At what dose does venlafaxine begin to
exhibit noradrenergic activity?
A. 37.5 mg/day
B. 75 mg/day
C. 150 mg/day
D. 225 mg/day
Correct Answer: C
Explanation: Venlafaxine exhibits noradrenergic reuptake inhibition at doses ≥150 mg/day,
contributing to its efficacy in anxiety and depression.
Question 8
Which adverse effect is most characteristic of buspirone that requires patient counseling?
A. Sedation
B. Weight gain
C. Delayed onset of action
D. Sexual dysfunction
Correct Answer: C
Explanation: Buspirone requires 2-4 weeks for full anxiolytic effect and does not provide
immediate relief like benzodiazepines.
Obsessive-Compulsive and Related Disorders
Comprehensive Board Practice Test — Psychopharmacology,
Psychiatric Disorders, Medication Management, Adverse Effects,
Drug Interactions & Clinical Decision-Making — 190 Multiple-Choice
Questions with Answers & Detailed Rationales
Domain 1: Mental Health Conditions and Disorders (36%)
Anxiety Disorders
Question 1
A 34-year-old female presents with excessive worry occurring more days than not for the
past eight months. She reports difficulty controlling the worry, restlessness, and sleep
disturbance. She denies panic attacks or avoidance of social situations. Which diagnosis is
most consistent with her presentation?
A. Panic Disorder
B. Generalized Anxiety Disorder
C. Social Anxiety Disorder
D. Adjustment Disorder with Anxiety
Correct Answer: B
Explanation: GAD requires excessive anxiety and worry for ≥6 months with difficulty
controlling worry plus ≥3 associated symptoms (restlessness, fatigue, concentration
problems, irritability, muscle tension, sleep disturbance).
Question 2
Which screening instrument is most appropriate for quantifying symptom severity in a
patient with suspected generalized anxiety disorder?
,A. PHQ-9
B. GAD-7
C. MDQ
D. AUDIT-C
Correct Answer: B
Explanation: GAD-7 is a validated 7-item self-report scale specifically designed to assess GAD
symptom severity and monitor treatment response.
Question 3
A 28-year-old male with GAD has not responded to an adequate trial of escitalopram. Which
agent has the strongest evidence for augmentation in treatment-resistant GAD?
A. Quetiapine
B. Propranolol
C. Buspirone
D. Hydroxyzine
Correct Answer: A
Explanation: Second-generation antipsychotics, particularly quetiapine, have the most robust
evidence for augmentation in treatment-resistant GAD when first-line SSRIs/SNRIs fail.
Question 4
Which benzodiazepine is preferred for a patient with significant hepatic impairment
requiring rapid anxiety control?
A. Diazepam
B. Chlordiazepoxide
C. Lorazepam
,D. Clonazepam
Correct Answer: C
Explanation: Lorazepam undergoes direct glucuronidation without active metabolites,
making it safer in hepatic impairment than diazepam, chlordiazepoxide, or clonazepam.
Question 5
A 45-year-old woman with panic disorder reports that her attacks occur unpredictably and
she now avoids driving. Which treatment approach has the strongest evidence for panic
disorder with agoraphobia?
A. Benzodiazepine monotherapy
B. SSRI plus cognitive-behavioral therapy
C. Propranolol as needed
D. Buspirone monotherapy
Correct Answer: B
Explanation: Combined SSRI and CBT is superior to either alone for panic disorder with
agoraphobia and addresses both biological and behavioral components.
Question 6
Which medication is FDA-approved for social anxiety disorder?
A. Sertraline
B. Venlafaxine ER
C. Paroxetine
D. Fluoxetine
Correct Answer: C
, Explanation: Paroxetine is FDA-approved for social anxiety disorder (social phobia), along
with extended-release venlafaxine and sertraline.
Question 7
A patient with GAD is initiated on venlafaxine XR. At what dose does venlafaxine begin to
exhibit noradrenergic activity?
A. 37.5 mg/day
B. 75 mg/day
C. 150 mg/day
D. 225 mg/day
Correct Answer: C
Explanation: Venlafaxine exhibits noradrenergic reuptake inhibition at doses ≥150 mg/day,
contributing to its efficacy in anxiety and depression.
Question 8
Which adverse effect is most characteristic of buspirone that requires patient counseling?
A. Sedation
B. Weight gain
C. Delayed onset of action
D. Sexual dysfunction
Correct Answer: C
Explanation: Buspirone requires 2-4 weeks for full anxiolytic effect and does not provide
immediate relief like benzodiazepines.
Obsessive-Compulsive and Related Disorders
